UBS Maintains Buy Rating for CymaBay Therapeutics: Here’s What You Need To Know
UBS has decided to maintain its Buy rating of CymaBay Therapeutics (NASDAQ:CBAY) and raise its price target from…
Investors Eye CymaBay’s AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due to
CymaBay Initiates AFFIRM, A Phase 3b/4 Study Evaluating The Effect Of Seladelpar On Clinical Outcomes In Patients With Cirrhosis Due To Primary Biliary Cholangitis
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar's accelerated
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.
Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session.
CymaBay Therapeutics’ Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Asensus Surgical (AMEX:ASXC) shares rose 37.2% to $0.4 during Thursday’s pre-market session. The company’s market cap stands…
Analyst Expectations for CymaBay Therapeutics’s Future
Analysts have provided the following ratings for CymaBay Therapeutics (NASDAQ:CBAY) within the last quarter: Bullish Somewhat Bullish Indifferent…
Benzinga’s Top Ratings Upgrades, Downgrades For August 14, 2023
Upgrades According to Barrington Research, the prior rating for Anika Therapeutics Inc (NASDAQ:ANIK) was changed from Market Perform…
Benzinga’s Top Ratings Upgrades, Downgrades For August 11, 2023
Upgrades For Alibaba Group Holding Ltd (NYSE:BABA), DZ Bank upgraded the previous rating of Hold to Buy. For…